315 related articles for article (PubMed ID: 17297459)
1. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs.
Le LQ; Parada LF
Oncogene; 2007 Jul; 26(32):4609-16. PubMed ID: 17297459
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.
Yang FC; Ingram DA; Chen S; Hingtgen CM; Ratner N; Monk KR; Clegg T; White H; Mead L; Wenning MJ; Williams DA; Kapur R; Atkinson SJ; Clapp DW
J Clin Invest; 2003 Dec; 112(12):1851-61. PubMed ID: 14679180
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
4. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
[TBL] [Abstract][Full Text] [Related]
5. Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention.
Parada LF; Kwon CH; Zhu Y
Cold Spring Harb Symp Quant Biol; 2005; 70():173-6. PubMed ID: 16869751
[TBL] [Abstract][Full Text] [Related]
6. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Williams KB; Largaespada DA
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
[TBL] [Abstract][Full Text] [Related]
7. The role of nerve microenvironment for neurofibroma development.
Liao CP; Pradhan S; Chen Z; Patel AJ; Booker RC; Le LQ
Oncotarget; 2016 Sep; 7(38):61500-61508. PubMed ID: 27517146
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis type 1 (NF1): diagnosis and management.
Ferner RE; Gutmann DH
Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
[TBL] [Abstract][Full Text] [Related]
9. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.
Staser K; Yang FC; Clapp DW
Curr Opin Hematol; 2010 Jul; 17(4):287-93. PubMed ID: 20571392
[TBL] [Abstract][Full Text] [Related]
10. Mast cells and the neurofibroma microenvironment.
Staser K; Yang FC; Clapp DW
Blood; 2010 Jul; 116(2):157-64. PubMed ID: 20233971
[TBL] [Abstract][Full Text] [Related]
11. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1.
Mund JA; Park S; Smith AE; He Y; Jiang L; Hawley E; Roberson MJ; Mitchell DK; Abu-Sultanah M; Yuan J; Bessler WK; Sandusky G; Chen S; Zhang C; Rhodes SD; Clapp DW
J Biol Chem; 2020 Jul; 295(29):9948-9958. PubMed ID: 32471868
[TBL] [Abstract][Full Text] [Related]
12. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
Yang FC; Chen S; Clegg T; Li X; Morgan T; Estwick SA; Yuan J; Khalaf W; Burgin S; Travers J; Parada LF; Ingram DA; Clapp DW
Hum Mol Genet; 2006 Aug; 15(16):2421-37. PubMed ID: 16835260
[TBL] [Abstract][Full Text] [Related]
13. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
Mashour GA; Ratner N; Khan GA; Wang HL; Martuza RL; Kurtz A
Oncogene; 2001 Jan; 20(1):97-105. PubMed ID: 11244508
[TBL] [Abstract][Full Text] [Related]
14. [Neurofibromatosis 1: pathogenesis and therapeutic strategies--a systematic review].
Kjærulff O; Wandall H
Ugeskr Laeger; 2012 Mar; 174(10):642-7. PubMed ID: 22395013
[TBL] [Abstract][Full Text] [Related]
15. Nf1-/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase.
Chen S; Burgin S; McDaniel A; Li X; Yuan J; Chen M; Khalaf W; Clapp DW; Yang FC
Am J Pathol; 2010 Dec; 177(6):3125-32. PubMed ID: 21037083
[TBL] [Abstract][Full Text] [Related]
16. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.
Perrin GQ; Fishbein L; Thomson SA; Thomas SL; Stephens K; Garbern JY; DeVries GH; Yachnis AT; Wallace MR; Muir D
J Neurosci Res; 2007 May; 85(6):1347-57. PubMed ID: 17335073
[TBL] [Abstract][Full Text] [Related]
17. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
18. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.
Brossier NM; Carroll SL
Brain Res Bull; 2012 May; 88(1):58-71. PubMed ID: 21855613
[TBL] [Abstract][Full Text] [Related]
19. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.
Le LQ; Shipman T; Burns DK; Parada LF
Cell Stem Cell; 2009 May; 4(5):453-63. PubMed ID: 19427294
[TBL] [Abstract][Full Text] [Related]
20. A porcine model of neurofibromatosis type 1 that mimics the human disease.
White KA; Swier VJ; Cain JT; Kohlmeyer JL; Meyerholz DK; Tanas MR; Uthoff J; Hammond E; Li H; Rohret FA; Goeken A; Chan CH; Leidinger MR; Umesalma S; Wallace MR; Dodd RD; Panzer K; Tang AH; Darbro BW; Moutal A; Cai S; Li W; Bellampalli SS; Khanna R; Rogers CS; Sieren JC; Quelle DE; Weimer JM
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
